Image Place holder

Michael Jaglal, MD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Jaglal recently completed a hematology/oncology fellowship at University of South Florida at Moffitt Cancer Center.  His research interests are in benign hematologic disorders: hemophilia, von Willebrand's disease, anemias, hemostasis and thrombosis disorders. Clinically, he will be a hematologist/oncologist within the MMG practice satellite located at Tampa General Hospital.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • Moffitt Cancer Center - Hematology/Oncology

Residency:

  • University of Louisville - Internal Medicine

Medical School:

  • St. George's University School of Medicine, Grenada, West Indies - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jaglal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun;5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
  • Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Jul. Pubmedid: 28749548.
  • Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neurooncol. 2017 Jan;19(1):99-108. Pubmedid: 27576871. Pmcid: PMC5193026.
  • Visweshwar N, Jaglal M, Booth C, Griffin P, Laber D. AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia. Ann Hematol. 2016 Oct;95(10):1747-1749. Pubmedid: 27449072. Pmcid: PMC4982880.
  • Balakrishnan A, Ledford R, Jaglal M. Temozolomide-induced biliary ductopenia: a case report. J Med Case Rep. 2016 Feb;10(1):33. Pubmedid: 26846183. Pmcid: PMC4743416.
  • Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb;56(2):500-502. Pubmedid: 24882264.
  • Griffin PT, Jaglal M. Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura. Blood. 2015 Feb;125(8):1349. Pubmedid: 25853149.
  • Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014 Sep;20(33):11894-11903. Pubmedid: 25206297. Pmcid: PMC4155383.
  • Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske T, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct;124(15):2354-2361. Pubmedid: 25161267.
  • Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel). 2014 Nov;6(4):2275-2295. Pubmedid: 25405526. Pmcid: PMC4276966.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.
  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.